Overall Score

Revenue Model

OMER remains a commercial-stage biotech with revenue still concentrated in a limited set of product/royalty streams.

Gross margin remains very high at 95.8%, supporting a strong underlying monetization profile.

Profitability

Reported net margin is positive at 32.5%, but operating profitability remains weak with operating margin at -189.5%.

Returns remain poor overall, with ROE at -109.4% and ROIC at -31.1%, indicating the business is not yet generating durable economic profits.

Cash Flow Quality

Cash generation remains inconsistent, with operating cash flow margin at -178.7% and free cash flow yield still negative.

Income quality is weak, suggesting reported earnings are not translating cleanly into cash flow.

Balance Sheet

Liquidity is adequate with a current ratio of 2.0x and quick ratio of 1.9x.

Leverage appears manageable overall, with debt-to-assets at 29.2% and net debt to EBITDA at 0.6x, though equity metrics remain distorted by negative book value.

Competitive Position

OMER shows strong gross profitability, but the business still lacks evidence of durable operating leverage.

The company’s valuation remains rich relative to sales, which implies the market is still pricing in meaningful future execution.